Eli Lilly Diabetes Drug Franchise Remains Strong, Analyst Praises Foundayo Trajectory
As Eli Lilly And Co (NYSE: LLY ) prepares to report third-quarter results in late October, Guggenheim analyst Seamus Fernandez maintains a Buy rating, with a raised price target from $1,273 to $1,284. While the company’s U.S. tirzepatide franchise remains strong, Fernandez says Foundayo’s trajectory is promising, with